Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with reviously treated advanced non-small-cell lung cancer

Tony S. Mok, S. L. Geater, N. Iannotti, S. Thongprasert, A. Spira, D. Smith, V. Lee, W. T. Lim, L. Reyderman, B. Wang, P. Gopalakrishna, F. Garzon, L. Xu, C. Reynolds

Research output: Contribution to journal › Article › peer-review